Okogen, Developer of Pink Eye Treatment, Raises $10 million
March 2, 2018
The San Diego Union Tribune covers Okogen’s receival of $10 million in Series A funding to further invest in treatments for viral conjunctivitis.
The San Diego Union Tribune covers Okogen’s receival of $10 million in Series A funding to further invest in treatments for viral conjunctivitis.
Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance the ongoing development of the company’s lead candidate for viral conjunctivitis (commonly known as pink eye), OKG-0301.
Okogen, Inc., a developer of ophthalmic anti-infectives, received a notice of allowance from the United States Patent and Trademark Office for the use of ranpirnase for the treatment of viral conjunctivitis. “The claims granted under 3IPOK1.0002US, in combination with the our existing in-licensed portfolio, further reinforce our strong intellectual property position,” said Brian M. Strem, Ph.D., Chief Executive Officer of Okogen.
OKG-0301 is a novel ribonuclease that can enter host cells and preferentially degrade viral tRNA leading to an inhibition of protein synthesis. This is an evaluation of the anti-adenoviral efficacy of topical OKG-0301 in the Ad5/NZW rabbit ocular model.
This article from Review of Ophthamology is a discussion of the various causes of conjunctivitis, and new therapeutic approaches on the horizon.
Okogen, Inc., a developer of ophthalmic anti-infectives has secured Ora, Inc., the leading ophthalmic Contract Research Organization, to conduct the clinical studies and lead the regulatory strategy of OKG-0301 for the treatment of adenoviral conjunctivitis.
© $year Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
8400 Belleview Drive, Suite 125
Plano, Texas 75024
USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000
AUS
